Biologically Active Substance
Rakuten Medical Raises $100 Million in Oversubscribed Series F for Photoimmunotherapy Platform
Rakuten Medical; Series F; $100M; photoimmunotherapy; cancer therapy; Alluminox; regulatory approval
Syncromune Appoints Dr. Stephen P. Dale as Chief Medical Officer
Syncromune; Stephen P. Dale; CMO; appointment; oncology; SYNC-T; biopharmaceutical
Crinetics Reports Over $5M in Q4 2025 PALSONIFY Revenue with Strong Launch Metrics
Crinetics; PALSONIFY; Palsonify; Q4 2025; revenue; $5M; acromegaly; enrollment forms; prescribers
Aktis Oncology Targets $181M-$209M in First Biotech IPO of 2026
Aktis Oncology; IPO; biotech; radiopharmaceutical; 2026; $181M; $200M
AstraZeneca Pays $100M Upfront, Up to $2B Total for Jacobio’s Pan-KRAS Inhibitor JAB-23E73
AstraZeneca; Jacobio Pharma; JAB-23E73; pan-KRAS inhibitor; cancer drug; licensing deal; $100M upfront; $2B milestones
GSK strikes RNA-based neuro and kidney disease collaboration with CAMP4 Therapeutics
GSK; CAMP4 Therapeutics; RNA therapeutics; regulatory RNA; antisense oligonucleotides; ASO; RAP Platform; neurodegenerative diseases; kidney disease; renal disease; gene upregulation; biotech collaboration; licensing deal; milestone payments; tiered royalties
Jim Lang Appointed to the Board of Directors of Halozyme Therapeutics
Jim Lang; Halozyme Therapeutics; Board of Directors; appointment; election; Bench International; biopharmaceutical; drug delivery platform; corporate governance; OptimizeRx; BioVie
Pharmas Write Big M&A Checks Again as Patent Urgency Seizes C-Suites
pharma M&A 2025; biotech acquisitions; patent cliff; pharma patent expirations; Novo Nordisk Akero deal; Johnson & Johnson Intra-Cellular acquisition; Merck Verona Pharma deal; Sanofi Blueprint Medicines acquisition; FGF21 MASH deals; 2025 healthcare deals
Specific Biologics Appoints Dr. Richard Glickman to Board of Directors
Specific Biologics; Richard Glickman; Board of Directors; biotechnology; genome editing
China’s fast, low-cost gene and cell therapy testing boom draws Western interest
China clinical trials; gene therapy; cell therapy; advanced therapy medicinal products; ATMP regulation China 2025; shortened clinical trial review; cheap clinical trials; Western biotech in China; NMPA CDE reforms; novel therapies testing